Skip to main content
. Author manuscript; available in PMC: 2020 May 1.
Published in final edited form as: Gynecol Oncol. 2019 Feb 23;153(2):217–222. doi: 10.1016/j.ygyno.2019.02.011

Figure 2.

Figure 2.

Kaplan-Meier curves for overall survival by CD3+ tumor infiltrating lymphocyte (TIL) score (high/low) in Panel A, CD68+ tumor associated macrophage (TAM) score (high/low) in Panel B, homologous recombination deficiency (HRD) in Panel C, and by CD3+ TIL score (high/low) and HRD in Panel D.